The US Food and Drug Administration (FDA) has authorized the marketing of 11 ZYN ULTRA moist oral nicotine pouch products for Philip Morris International Inc. (NYSE: PM). The approval covers all nine 9mg variants and one 11mg variant of the tobacco-free product line.

This regulatory action strengthens Philip Morris International’s position in the US smoke-free category. The FDA issued Marketing Granted Orders to PMI’s US affiliate, Swedish Match USA Inc., following a scientific review. Additional 11mg variants remain under review.

Product Portfolio Expansion

The authorized products feature higher moisture content compared to standard pouches. They are free of tobacco leaf. The approvals build on earlier FDA authorizations for ZYN in multiple flavors and lower nicotine strengths (3mg and 6mg).

Authorized Variants

Stacey Kennedy, CEO of PMI US, stated the decision builds on ZYN’s position as America’s leading smoke-free product brand. The company aims to expand choices for the 45 million Americans who consume nicotine products.

Regulatory Context

The FDA determined that permitting the marketing of these new tobacco products is appropriate for the protection of public health. This follows recent modified risk tobacco product orders for certain previously authorized ZYN nicotine pouches.

Philip Morris International began commercialization of ZYN ULTRA in June 2026 under recent FDA guidance. The company leads the industry in securing FDA authorizations for smoke-free products.

Business Impact

As of December 31, 2025, PMI estimated over 43 million legal-age consumers worldwide used its smoke-free products. The smoke-free business accounted for approximately 42% of PMI’s second-quarter 2026 total net revenues.

PMI has invested over $16 billion since 2008 to develop and commercialize innovative smoke-free products. The company operates manufacturing facilities in Aurora, Colorado; Owensboro, Kentucky; and Wilson, North Carolina.

What the Numbers Show

The authorization of high-nicotine variants (9mg and 11mg) indicates a strategic shift toward capturing consumers seeking stronger nicotine delivery without tobacco leaf. With smoke-free products already contributing 42% of Q2FY26 net revenues, expanding the authorized portfolio supports revenue diversification away from traditional cigarettes.

Three major consumer staples companies — Philip Morris International Inc., Keurig Dr Pepper Inc., and Constellation Brands Inc. — have drawn fresh attention from top-rated Wall Street analysts, with updates on price targets and ratings reflecting their status as high-yield defensive plays. These firms, all offering dividend yields exceeding 3%, are being closely watched as investors seek stability amid market turbulence. Recent corporate actions include raised earnings guidance from Philip Morris and Constellation Brands, while Keurig Dr Pepper is set to release its second-quarter financial results on August 6.

Philip Morris International Inc. (NYSE: PM)

Philip Morris International continues to attract analyst interest despite slight downward adjustments in price targets by two major banks. The company reported better-than-expected second-quarter financial results on July 22 and subsequently raised its FY26 GAAP EPS guidance, signaling strong operational performance.

The dividend yield for Philip Morris stands at 3.03%. While both Stifel and JP Morgan maintained positive outlooks with Buy and Overweight ratings respectively, they reduced their price targets. Jared Dinges of JP Morgan, who holds a 70% accuracy rate, cut the target to $185, while Matthew Smith of Stifel lowered his to $195.

Keurig Dr Pepper Inc (NASDAQ: KDP)

Keurig Dr Pepper has seen upward revisions in price targets from two prominent analysts ahead of its upcoming earnings report. The company announced it will release its second-quarter financial results before the opening bell on Thursday, August 6.

With a dividend yield of 3.05%, Keurig Dr Pepper remains a favorite among income-focused investors. Peter Grom of UBS and Filippo Falorni of Citigroup both maintained Buy ratings while increasing their price targets. Grom raised his target to $38, citing strong fundamentals, while Falorni set his at $37.

Constellation Brands Inc (NYSE: STZ)

Constellation Brands received mixed signals from analysts, with one firm cutting its price target while another maintained a significantly higher outlook. On June 30, the company reported better-than-expected first-quarter financial results and raised its FY27 GAAP EPS guidance.

Trading with a dividend yield of 3.12%, Constellation Brands shows divergent analyst views. Lauren Lieberman of Barclays reduced the price target to $132 while maintaining an Equal-Weight rating. In contrast, Andrew Strelzik of BMO Capital maintained an Outperform rating with a much higher price target of $190.

What the Numbers Show

The divergence in analyst actions across these three high-yield stocks highlights differing interpretations of near-term valuation versus long-term growth potential. While Philip Morris and Constellation Brands have both raised earnings guidance following strong quarterly reports, analysts like those at Stifel and Barclays have trimmed price targets, possibly reflecting cautious sentiment on multiple expansion. Conversely, the upward revisions for Keurig Dr Pepper by UBS and Citigroup suggest confidence in pre-earnings momentum. Investors should note that despite the yield appeal, price target cuts from high-accuracy analysts such as Jared Dinges (70%) warrant careful consideration of downside risk.